Company / Operating Cash Flow
Sunshine Biopharma Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$12.5M
FY2025
5-year range
-$12.5M / -$657.3K
FY2021-FY2025
Trend
-42.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has declined for 5 consecutive years, from -$495,798 in FY2020 to -$13M in FY2025.
Based on SEC 10-K filings.
-$13M in FY2025.
Declined from -$5M to -$13M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Sunshine Biopharma Inc.'s operating cash flow has declined for 5 consecutive years.
- In FY2025, operating cash flow decreased 42.7% year-over-year.
- Peak operating cash flow was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$12.5M | -42.7% |
| FY2024 | -$8.8M | -67.2% |
| FY2023 | -$5.2M | -186.9% |
| FY2022 | -$1.8M | -178.3% |
| FY2021 | -$657.3K | -32.6% |
| FY2020 | -$495.8K | +3.3% |
| FY2019 | -$512.8K | +5.7% |
| FY2018 | -$543.5K | -73.0% |
| FY2017 | -$314.2K | +63.8% |
| FY2016 | -$867.6K | -61.1% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026